Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
IEEE Trans Vis Comput Graph ; 29(4): 2020-2035, 2023 04.
Article in English | MEDLINE | ID: mdl-34965212

ABSTRACT

Diffusion tensor imaging (DTI) has been used to study the effects of neurodegenerative diseases on neural pathways, which may lead to more reliable and early diagnosis of these diseases as well as a better understanding of how they affect the brain. We introduce a predictive visual analytics system for studying patient groups based on their labeled DTI fiber tract data and corresponding statistics. The system's machine-learning-augmented interface guides the user through an organized and holistic analysis space, including the statistical feature space, the physical space, and the space of patients over different groups. We use a custom machine learning pipeline to help narrow down this large analysis space and then explore it pragmatically through a range of linked visualizations. We conduct several case studies using DTI and T1-weighted images from the research database of Parkinson's Progression Markers Initiative.


Subject(s)
Diffusion Tensor Imaging , Neurodegenerative Diseases , Humans , Neurodegenerative Diseases/diagnostic imaging , Computer Graphics , Brain/diagnostic imaging , Databases, Factual
2.
Eur J Nucl Med Mol Imaging ; 49(9): 3162-3172, 2022 07.
Article in English | MEDLINE | ID: mdl-35165788

ABSTRACT

PURPOSE: Chronic traumatic encephalopathy refers to a neurodegenerative disease resulting from repetitive head injury of participants in contact sports. Similar to other neurodegenerative diseases, neuroinflammation is thought to play a role in the onset and progression of the disease. Limited knowledge is available regarding the neuroinflammatory consequences of repetitive head injury in currently active contact sports athletes. PET imaging of the 18-kDa translocator protein (TSPO) allows quantification of microglial activation in vivo, a marker of neuroinflammation. METHODS: Eleven rank A kickboxers and 11 age-matched controls underwent TSPO PET using [11C]-PK11195, anatomical MRI, diffusion tensor imaging, and neuropsychological testing. Relevant imaging parameters were derived and correlated with the outcomes of the neuropsychological testing. RESULTS: On a group level, no statistically significant differences were detected in non-displaceable binding potential (BPND) using PET. Individually, 3 kickboxers showed increased BPNDs in widespread regions of the brain without a correlation with other modalities. Increased FA was observed in the superior corona radiata bilaterally. DTI parameters in other regions did not differ between groups. CONCLUSION: Despite negative results on a group level, individual results suggest that neuroinflammation may be present as a consequence of repetitive head injury in active kickboxers. Future studies using a longitudinal design may determine whether the observed TSPO upregulation is related to the future development of neuropsychiatric symptoms.


Subject(s)
Athletic Injuries , Craniocerebral Trauma , Neurodegenerative Diseases , Neuroinflammatory Diseases , Athletic Injuries/diagnostic imaging , Brain/metabolism , Craniocerebral Trauma/diagnostic imaging , Craniocerebral Trauma/metabolism , Diffusion Tensor Imaging , Humans , Martial Arts/injuries , Neurodegenerative Diseases/diagnostic imaging , Neuroinflammatory Diseases/diagnostic imaging , Positron-Emission Tomography/methods , Receptors, GABA/metabolism
3.
Neuroimage ; 245: 118752, 2021 12 15.
Article in English | MEDLINE | ID: mdl-34823024

ABSTRACT

AIMS: Non-invasive measures of brain iron content would be of great benefit in neurodegeneration with brain iron accumulation (NBIA) to serve as a biomarker for disease progression and evaluation of iron chelation therapy. Although magnetic resonance imaging (MRI) provides several quantitative measures of brain iron content, none of these have been validated for patients with a severely increased cerebral iron burden. We aimed to validate R2* as a quantitative measure of brain iron content in aceruloplasminemia, the most severely iron-loaded NBIA phenotype. METHODS: Tissue samples from 50 gray- and white matter regions of a postmortem aceruloplasminemia brain and control subject were scanned at 1.5 T to obtain R2*, and biochemically analyzed with inductively coupled plasma mass spectrometry. For gray matter samples of the aceruloplasminemia brain, sample R2* values were compared with postmortem in situ MRI data that had been obtained from the same subject at 3 T - in situ R2*. Relationships between R2* and tissue iron concentration were determined by linear regression analyses. RESULTS: Median iron concentrations throughout the whole aceruloplasminemia brain were 10 to 15 times higher than in the control subject, and R2* was linearly associated with iron concentration. For gray matter samples of the aceruloplasminemia subject with an iron concentration up to 1000 mg/kg, 91% of variation in R2* could be explained by iron, and in situ R2* at 3 T and sample R2* at 1.5 T were highly correlated. For white matter regions of the aceruloplasminemia brain, 85% of variation in R2* could be explained by iron. CONCLUSIONS: R2* is highly sensitive to variations in iron concentration in the severely iron-loaded brain, and might be used as a non-invasive measure of brain iron content in aceruloplasminemia and potentially other NBIA disorders.


Subject(s)
Brain/diagnostic imaging , Brain/metabolism , Ceruloplasmin/deficiency , Iron Metabolism Disorders/diagnostic imaging , Iron Metabolism Disorders/metabolism , Iron/metabolism , Magnetic Resonance Imaging/methods , Neurodegenerative Diseases/diagnostic imaging , Neurodegenerative Diseases/metabolism , Autopsy , Ceruloplasmin/metabolism , Humans , Male , Middle Aged , Netherlands , Phenotype
4.
J Am Coll Radiol ; 17(5S): S175-S187, 2020 May.
Article in English | MEDLINE | ID: mdl-32370961

ABSTRACT

Movement disorders and neurodegenerative diseases are a variety of conditions that involve progressive neuronal degeneration, injury, or death. Establishing the correct diagnosis of a movement disorder or neurodegenerative process can be difficult due to the variable features of these conditions, unusual clinical presentations, and overlapping symptoms and characteristics. MRI has an important role in the initial assessment of these patients, although a combination of imaging and laboratory and genetic tests is often needed for complete evaluation and management. This document summarizes the imaging appropriateness data for rapidly progressive dementia, chorea, Parkinsonian syndromes, suspected neurodegeneration with brain iron accumulation, and suspected motor neuron disease. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.


Subject(s)
Movement Disorders , Neurodegenerative Diseases , Evidence-Based Medicine , Humans , Magnetic Resonance Imaging , Movement Disorders/diagnostic imaging , Neurodegenerative Diseases/diagnostic imaging , Societies, Medical , United States
5.
Molecules ; 25(10)2020 May 14.
Article in English | MEDLINE | ID: mdl-32422902

ABSTRACT

Many neurological disorders are related to synaptic loss or pathologies. Before the boom of positrons emission tomography (PET) imaging of synapses, synaptic quantification could only be achieved in vitro on brain samples after autopsy or surgical resections. Until the mid-2010s, electron microscopy and immunohistochemical labelling of synaptic proteins were the gold-standard methods for such analyses. Over the last decade, several PET radiotracers for the synaptic vesicle 2A protein have been developed to achieve in vivo synapses visualization and quantification. Different strategies were used, namely radiolabelling with either 11C or 18F, preclinical development in rodent and non-human primates, and binding quantification with different kinetic modelling methods. This review provides an overview of these PET tracers and underlines their perspectives and limitations by focusing on radiochemical aspects, as well as preclinical proof-of-concept and the main clinical outcomes described so far.


Subject(s)
Brain/diagnostic imaging , Neurodegenerative Diseases/diagnostic imaging , Positron-Emission Tomography/methods , Pyridines/pharmacokinetics , Pyrrolidines/pharmacokinetics , Pyrrolidinones/pharmacokinetics , Synaptic Vesicles/pathology , Animals , Brain/metabolism , Carbon Radioisotopes , Clinical Trials as Topic , Drug Evaluation, Preclinical , Fluorine Radioisotopes , Humans , Macaca mulatta , Neurodegenerative Diseases/metabolism , Neurodegenerative Diseases/pathology , Neurons/metabolism , Neurons/pathology , Positron-Emission Tomography/standards , Proof of Concept Study , Pyridines/chemical synthesis , Pyrrolidines/chemical synthesis , Pyrrolidinones/chemical synthesis , Radiopharmaceuticals/chemical synthesis , Radiopharmaceuticals/pharmacokinetics , Rodentia , Synaptic Vesicles/metabolism
6.
Magn Reson Imaging ; 70: 29-35, 2020 07.
Article in English | MEDLINE | ID: mdl-32114188

ABSTRACT

OBJECTIVES: Aceruloplasminemia (ACP) is a rare autosomal recessive disorder characterized by intracranial and visceral iron overload. With R2*-based imaging or quantitative susceptibility mapping (QSM), it is feasible to measure iron in the brain quantitatively, although to date this has not yet been done for patients with ACP. The aim of this study was to provide quantitative iron measurements for each affected brain region in an ACP patient with the potential to do so in all future ACP patients. This may shed light on the link between brain iron metabolism and the territories affected by ceruloplasmin function. METHODS: We imaged a patient with ACP using a 3T magnetic resonance imaging scanner with a fifteen-channel head coil. We manually demarcated gray matter and white matter on the Strategically Acquired Gradient Echo (STAGE) images, and calculated values for susceptibility and R2* in these regions. Correlation analysis was performed between the R2* values and the susceptibility values. RESULTS: Besides the usual territories affected in ACP, we also discovered that the mammillary bodies and the lateral habenulae had significant increases in iron, and the hippocampus was severely affected both in terms of iron content and abnormal tissue signal. We also noted that the iron in the cortical gray matter appeared to be deposited in the inner layers. Moreover, several pathways between the superior colliculus and the pulvinar thalamus, between the caudate and putamen anteriorly and between the caudate and pulvinar thalamus posteriorly were also evident. Finally, R2* correlated strongly with the QSM data (R2 = 0.67, t = 6.78, p < 0.001). CONCLUSION: QSM and R2* have proven to be sensitive and quantitative means by which to measure iron content in the brain. Our findings included several newly noted affected brain regions of iron overload and provided some new aspects of iron metabolism in ACP that may be further applicable to other pathologic conditions. Furthermore, our study may pave the way for assessing efficacy of iron chelation therapy in these patients and for other common iron related neurodegenerative disorders.


Subject(s)
Ceruloplasmin/deficiency , Iron Metabolism Disorders/metabolism , Iron/metabolism , Neurodegenerative Diseases/metabolism , Adult , Brain/diagnostic imaging , Brain/metabolism , Ceruloplasmin/metabolism , Female , Humans , Iron Metabolism Disorders/diagnostic imaging , Male , Middle Aged , Neurodegenerative Diseases/diagnostic imaging
8.
J Neuroimmune Pharmacol ; 14(2): 295-311, 2019 06.
Article in English | MEDLINE | ID: mdl-30488353

ABSTRACT

Cortical cerebral ischemia elicits neuroinflammation as well as secondary neuronal degeneration in remote areas. Locally distinct and specific secondary neurodegeneration affecting thalamic nuclei connected to cortical areas highlights such processes. Osteopontin (OPN) is a cytokine-like glycoprotein that is excreted in high amounts after cerebral ischemia and exerts various immunomodulatory functions. We here examined putative protective effects of OPN in secondary thalamic degeneration. We subjected male Wistar rats to photothrombosis and subsequently injected OPN or placebo intracerebroventricularly. Immunohistochemical and fluorescence staining was used to detect the extent of neuronal degeneration and microglia activation. Ex vivo autoradiography with radiotracers available for human in vivo PET studies, i.e., CIS-4-[18F]Fluor-D-Proline (D-cis-[18F]FPRO), and [6-3H]thymidine ([3H]thymidine), confirmed degeneration and proliferation, respectively. We found secondary neurodegeneration in the thalamus characterized by microglial activation and neuronal loss. Neuronal loss was restricted to areas of microglial infiltration. Treatment with OPN significantly decreased neurodegeneration, inflammation and microglial proliferation. Microglia displayed morphological signs of activation without expressing markers of M1 or M2 polarization. D-CIS-[18F]FPRO-uptake mirrored attenuated degeneration in OPN-treated animals. Notably, [3H]thymidine and BrdU-staining revealed increased stem cell proliferation after treatment with OPN. The data suggest that OPN is able to ameliorate secondary neurodegeneration in thalamic nuclei. These effects can be visualized by radiotracers D-CIS-[18F]FPRO and [3H]thymidine, opening new vistas for translational studies. Graphical Abstract Intracerebroventricular injection of osteopontin attenuates thalamic degeneration after cortical ischemia (pink area). Disruption of thalamocortical connections (blue) and degeneration of thalamic nuclei (encircled) leads to microglia activation. Osteopontin protects from both neurodegeneration and microglia activation as assessed by histological analysis and autoradiograpic studies.


Subject(s)
Neurodegenerative Diseases/prevention & control , Osteopontin/pharmacology , Stroke/pathology , Thalamic Diseases/prevention & control , Thalamus/pathology , Animals , Brain Ischemia/pathology , Macrophage Activation/drug effects , Male , Microglia/drug effects , Neurodegenerative Diseases/diagnostic imaging , Neurodegenerative Diseases/pathology , Neurons/pathology , Phagocytes/drug effects , Phagocytes/pathology , Positron-Emission Tomography , Rats , Rats, Wistar , Stroke/complications , Stroke/diagnostic imaging , Thalamic Diseases/diagnostic imaging , Thalamic Diseases/pathology , Thalamus/diagnostic imaging , Thrombosis/pathology
9.
Alzheimers Res Ther ; 10(1): 114, 2018 11 06.
Article in English | MEDLINE | ID: mdl-30400991

ABSTRACT

BACKGROUND: Low haemoglobin is highly prevalent among the elderly and has been associated with dementia. However, the mechanisms underlying this association with cognitive dysfunction, either through cerebrovascular disease or neurodegeneration, remain poorly understood. We aimed to examine the association of decreased haemoglobin levels with markers of cerebral small vessel disease (CSVD), neurodegeneration and cognitive impairment in an elderly Asian population. METHODS: A total of 796 Chinese, Malay and Indian participants aged 60 years and older from the Epidemiology of Dementia in Singapore study were included in this study. After providing information on demographics, anthropometry and cardiovascular risk factors, participants underwent 3-T brain magnetic resonance imaging (MRI) to measure markers of CSVD, including cerebral microbleeds, cortical cerebral microinfarcts, lacunes, enlarged perivascular spaces and white matter hyperintensities, as well as neurodegenerative markers, including cortical thickness and subcortical structure volumes quantified using FreeSurfer. Cognition was assessed using a detailed neuropsychological assessment. Logistic and linear regression models were constructed, adjusting for age, gender, education, race, body mass index, smoking, hypertension, hyperlipidaemia, diabetes, glomerular filtration rate and other MRI markers, to test the association between haemoglobin levels and the MRI markers and cognition. RESULTS: Decreased haemoglobin levels were associated with cerebral microbleeds, specifically lobar microbleeds (OR, 1.21; 95% CI, 1.04-1.40; p = 0.015). Decreased haemoglobin levels were also associated with occipital cortical thinning (mean difference, - 0.011; 95% CI, - 0.019, - 0.004; p = 0.003) and smaller accumbens volume (mean difference, - 0.01; 95% CI, - 0.02, 0.00; p = 0.005). A significant association was also observed between decreased haemoglobin levels and poorer global cognitive performance (mean difference, - 0.04; 95% CI, - 0.09, 0.00; p = 0.048). In cognitive domain analysis, associations were again observed between decreased haemoglobin levels and worse performance on attention (mean difference, - 0.05; 95% CI, - 0.10, - 0.01; p = 0.028) and language (mean difference, - 0.06; 95% CI, - 0.12, 0.00; p = 0.048) domains; however, these associations did not survive multiple comparison. CONCLUSIONS: Decreased haemoglobin levels were associated with lobar microbleeds, neurodegenerative markers and cognitive dysfunction. Future studies should ascertain whether iron, folate or vitamin B12 supplementation is able to ameliorate the onset and progression of cognitive impairment and dementia associated with low haemoglobin.


Subject(s)
Brain/diagnostic imaging , Cerebral Small Vessel Diseases/blood , Cerebral Small Vessel Diseases/diagnostic imaging , Cognitive Dysfunction/blood , Cognitive Dysfunction/diagnostic imaging , Hemoglobins/analysis , Neurodegenerative Diseases/blood , Neurodegenerative Diseases/diagnostic imaging , Aged , Biomarkers/blood , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neuropsychological Tests
10.
J Neurol Sci ; 388: 150-154, 2018 05 15.
Article in English | MEDLINE | ID: mdl-29627011

ABSTRACT

INTRODUCTION: Idiopathic basal ganglia calcification (IBGC), also called Fahr's disease or recently primary familial brain calcification (PFBC), is characterized by abnormal deposits of minerals including calcium mainly and phosphate in the brain. Mutations in SLC20A2 (IBGC1 (merged with former IBGC2 and IBGC3)), which encodes PiT-2, a phosphate transporter, is the major cause of IBGC. Recently, Slc20a2-KO mice have been showed to have elevated levels of inorganic phosphorus (Pi) in cerebrospinal fluid (CSF); however, CSF Pi levels in patients with IBGC have not been fully examined. METHODS: We investigated the cases of 29 patients with IBGC including six patients with SLC20A2 mutation and three patients with PDGFB mutation, and 13 controls. The levels of sodium (Na), potassium (K), chloride (Cl), calcium (Ca), and Pi in sera and CSF were determined by potentiometry and colorimetry. Moreover, clinical manifestations were investigated in the IBGC patients with high Pi levels in CSF. RESULTS: The study revealed that the average level of Pi in the CSF of the total group of patients with IBGC is significantly higher than that of the control group, and the levels of Pi in CSF of the IBGC patients with SLC20A2 mutations are significantly higher than those of the IBGC patients with PDGFB mutations, the other IBGC patients and controls. CONCLUSION: Results of this study suggest that the levels of CSF Pi will be a good biomarker for IBGC1.


Subject(s)
Basal Ganglia Diseases/cerebrospinal fluid , Basal Ganglia Diseases/genetics , Calcinosis/cerebrospinal fluid , Calcinosis/genetics , Mutation , Neurodegenerative Diseases/cerebrospinal fluid , Neurodegenerative Diseases/genetics , Phosphorus/cerebrospinal fluid , Sodium-Phosphate Cotransporter Proteins, Type III/genetics , Adolescent , Adult , Basal Ganglia/diagnostic imaging , Basal Ganglia Diseases/diagnostic imaging , Biomarkers/cerebrospinal fluid , Calcinosis/diagnostic imaging , Female , Humans , Male , Middle Aged , Neurodegenerative Diseases/diagnostic imaging , Proto-Oncogene Proteins c-sis/genetics , Young Adult
11.
J Neurol ; 265(5): 1089-1095, 2018 May.
Article in English | MEDLINE | ID: mdl-29502317

ABSTRACT

BACKGROUND: Whilst the dangers of 'legal highs' have been widely publicised in the media, very few cases of the neurological syndrome associated with the inhalation of nitrous oxide (N2O) have been reported. Here we set out to raise awareness of subacute degeneration of the spinal cord arising from recreational N2O use so that formal surveillance programs and public health interventions can be designed. METHODS: Case series documenting the clinical and investigational features of ten consecutive cases of subacute degeneration of the spinal cord presenting to a hospital with a tertiary neurosciences service in East London. RESULTS: Sensory disturbance in the lower (± upper) limbs was the commonest presenting feature, along with gait abnormalities and sensory ataxia. MRI imaging of the spine showed the characteristic features of dorsal column hyperintensity on T2 weighted sequences. Serum B12 levels may be normal because subacute degeneration of the spinal cord in this situation is triggered by functional rather than absolute B12 deficiency. DISCUSSION: A high index of suspicion is required to prompt appropriate investigation, make the diagnosis and commence treatment early. This is the largest reported series of patients with subacute degeneration of the spinal cord induced by recreational use of N2O. However, the number of patients admitted to hospital likely represents the 'tip of the iceberg', with many less severe presentations remaining undetected. After raising awareness, attention should focus on measuring the extent of the problem, the groups affected, and devising ways to prevent potentially long-term neurological damage.


Subject(s)
Neurodegenerative Diseases/chemically induced , Nitrous Oxide/toxicity , Spinal Cord Diseases/chemically induced , Substance-Related Disorders/etiology , Adolescent , Adult , Ataxia/chemically induced , Ataxia/diagnostic imaging , Ataxia/physiopathology , Ataxia/therapy , Diagnosis, Differential , Female , Humans , Magnetic Resonance Imaging , Male , Neurodegenerative Diseases/diagnostic imaging , Neurodegenerative Diseases/physiopathology , Neurodegenerative Diseases/therapy , Retrospective Studies , Spinal Cord/diagnostic imaging , Spinal Cord Diseases/diagnostic imaging , Spinal Cord Diseases/physiopathology , Spinal Cord Diseases/therapy , Substance-Related Disorders/diagnostic imaging , Substance-Related Disorders/physiopathology , Substance-Related Disorders/therapy , Vitamin B 12/blood , Young Adult
13.
Ultraschall Med ; 37(6): 604-608, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27486795

ABSTRACT

Purpose: Transcranial B-mode sonography (TCS) of brain parenchyma is increasingly used as a diagnostic tool for movement disorders. Accordingly, experimental B-Mode Assist software was developed to enable digitized analysis of the echogenicity of predefined brain regions. The aim of the study was to assess the reproducibility of digitized TCS image analysis of the insula. Materials and Methods: A total of 130 patients with an indication for neurosonological examination were screened for participation in the study. The insula was imaged from the right temporal bone window using Virtual Navigator and TCS-MRI (magnetic resonance imaging) fusion imaging. All subjects were examined three times by two experienced sonographers. Corresponding images of the insula in the axial thalamic plane were encoded and digitally analyzed. Interclass correlation coefficient (ICC) and Spearman's rank correlation coefficient were used for the assessment of intra- and inter-reader as well as intra- and inter-investigator reliabilities. Results: TCS images of 114 patients were evaluated (21 patients with TIA, 53 patients with headache, 18 patients with essential tremor, 22 patients with neurodegerative disease). 16 patients were excluded from analysis due to insufficient bone window. The intra-reader, inter-reader, intra-investigator and inter-investigator ICCs/Spearman's rank correlation coefficients were 0.995/0.993, 0.937/0.921, 0.969/0.961 and 0.875/0.858, resp. Conclusion: The present study demonstrates a high reliability to reproduce echogenicity values of the insula using digitized image analysis and TCS-MRI fusion images with almost perfect intra-reader, inter-reader, intra-investigator and inter-investigator agreement.


Subject(s)
Cerebral Cortex/diagnostic imaging , Contrast Media , Essential Tremor/diagnostic imaging , Headache/diagnostic imaging , Image Enhancement/methods , Image Interpretation, Computer-Assisted/methods , Ischemic Attack, Transient/diagnostic imaging , Magnetic Resonance Imaging/methods , Multimodal Imaging/methods , Neurodegenerative Diseases/diagnostic imaging , Ultrasonography, Doppler, Transcranial/methods , Female , Humans , Infant, Newborn , Observer Variation , Pregnancy , Reproducibility of Results , Statistics as Topic , Thalamus/diagnostic imaging , User-Computer Interface
14.
MAGMA ; 29(3): 491-501, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27059982

ABSTRACT

OBJECTIVE: To demonstrate that high resolution (1)H semi-LASER MRSI acquired at 7 T permits discrimination of metabolic patterns of different thalamic nuclei. MATERIALS AND METHODS: Thirteen right-handed healthy volunteers were explored at 7 T using a high-resolution 2D-semi-LASER (1)H-MRSI sequence to determine the relative levels of N-Acetyl Aspartate (NAA), choline (Cho) and creatine-phosphocreatine (Cr) in eight VOIs (volume <0.3 ml) centered on four different thalamic nuclei located on the Oxford thalamic connectivity atlas. Post-processing was done using the CSIAPO software. Chemical shift displacement of metabolites was evaluated on a phantom and correction factors were applied to in vivo data. RESULTS: The global assessment (ANOVA p < 0.05) of the neurochemical profiles (NAA, Cho and Cr levels) with thalamic nuclei and hemispheres as factors showed a significant global effect (F = 11.98, p < 0.0001), with significant effect of nucleus type (p < 0.0001) and hemisphere (p < 0.0001). Post hoc analyses showed differences in neurochemical profiles between the left and the right hemisphere (p < 0.05), and differences in neurochemical profiles between nuclei within each hemisphere (p < 0.05). CONCLUSION: For the first time, using high resolution 2D-PRESS semi-LASER (1)H-MRSI acquired at 7 T, we demonstrated that the neurochemical profiles were different between thalamic nuclei, and that these profiles were dependent on the brain hemisphere.


Subject(s)
Magnetic Resonance Imaging , Magnetic Resonance Spectroscopy , Thalamus/diagnostic imaging , Adult , Analysis of Variance , Aspartic Acid/analogs & derivatives , Aspartic Acid/analysis , Brain/diagnostic imaging , Choline/analysis , Creatine/analysis , Female , Healthy Volunteers , Humans , Lasers , Male , Neurodegenerative Diseases/diagnostic imaging , Phantoms, Imaging , Phosphocreatine/analogs & derivatives , Phosphocreatine/analysis , Software , Spectrophotometry , Thalamus/metabolism , Young Adult
15.
J Nucl Med ; 56(7): 1048-54, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26025960

ABSTRACT

UNLABELLED: Translocator protein (TSPO) is expressed at a low level in healthy brain and is upregulated during inflammatory processes that may occur in neurodegenerative diseases. Thus, TSPO may be a suitable in vivo indicator of neurodegeneration. Here, we quantified the (18)F-DPA-714 radioligand in healthy TSPO-genotyped volunteers and developed a method to eliminate the need for invasive arterial blood sampling. METHODS: Ten controls (7 high-affinity binders [HABs] and 3 mixed-affinity binders [MABs]) underwent (18)F-DPA-714 PET with arterial and venous sampling. (18)F-DPA-714 binding was quantified with a metabolite-corrected arterial plasma input function, using the 1- and 2-tissue-compartment models (TCMs) as well as the Logan analysis to estimate total volume distribution (V(T)) in the regions of interest. Alternative quantification methods were tested, including tissue-to-plasma ratio or population-based input function approaches normalized by late time points of arterial or venous samples. RESULTS: The distribution pattern of (18)F-DPA-714 was consistent with the known distribution of TSPO in humans, with the thalamus displaying the highest binding and the cerebellum the lowest. The 2-TCM best described the regional kinetics of (18)F-DPA-714 in the brain, with good identifiability (percentage coefficient of variation < 5%). For each region of interest, V(T) was 47.6% ± 6.3% higher in HABs than in MABs, and estimates from the 2-TCM and the Logan analyses were highly correlated. Equilibrium was reached at 60 min after injection. V(T) calculated with alternative methods using arterial samples was strongly and significantly correlated with that calculated by the 2-TCM. Replacement of arterial with venous sampling in these methods led to a significant but lower correlation. CONCLUSION: Genotyping of subjects is a prerequisite for a reliable quantification of (18)F-DPA-714 PET images. The 2-TCM and the Logan analyses are accurate methods to estimate (18)F-DPA-714 V(T) in the human brain of both HAB and MAB individuals. Population-based input function and tissue-to-plasma ratio with a single arterial sample are promising alternatives to classic arterial plasma input function. Substitution with venous samples is promising but still requires methodologic improvements.


Subject(s)
Fluorine Radioisotopes/chemistry , Pyrazoles/chemistry , Pyrimidines/chemistry , Receptors, GABA/metabolism , Adult , Brain/diagnostic imaging , Cerebellum/diagnostic imaging , Female , Genotype , Healthy Volunteers , Humans , Image Processing, Computer-Assisted , Inflammation/pathology , Ligands , Male , Middle Aged , Neurodegenerative Diseases/diagnostic imaging , Polymorphism, Genetic , Positron-Emission Tomography , Protein Binding , Thalamus/diagnostic imaging
16.
Intern Med ; 50(22): 2775-81, 2011.
Article in English | MEDLINE | ID: mdl-22082889

ABSTRACT

OBJECTIVE: Because it is often difficult to precisely diagnose and distinguish progressive supranuclear palsy (PSP) from corticobasal degeneration (CBD), multiple system atrophy-parkinsonism (MSA-P) and Parkinson's disease (PD) at the onset of the disease, we compared the patients and clarified the features of these diseases. METHODS: We compared 77 PSP, 26 CBD, 26 MSA-P and 166 PD patients from clinical and imaging points of view including cerebral blood flow (CBF) in the frontal eye field. RESULTS: The clinical characteristics of PSP were supranuclear gaze disturbance, optokinetic nystagmus (OKN) impairment and falls at the first visit. On head MRI, midbrain tegmentum atrophy was much more frequently detected in PSP than in all of the other groups. Heart-to-mediastinum average count ratio (H/M) in iodine-123 meta-iodobenzyl guanidine ((123)I-MIBG) myocardial scintigraphy was not decreased in PSP, CBD, MSA-P and PD-Yahr 1 (-1), but patients of PD-2, 3, 4 and 5 showed a significant decrease compared with the PSP group. The CBF in the left frontal eye field of PD-3 group and that in right frontal eye field of PD-3 and PD-4 groups were lower than that of PSP group, although other groups showed a tendency without a significant decrease compared with PSP group. CONCLUSION: PSP is distinguishable from CBD, MSA-P and PD even at the early stage with extra-ocular movement (EOM) disturbance, falls, atrophy of the midbrain tegmentum, and H/M in (123)I-MIBG myocardial scintigraphy, and the reduction of CBF in area 8 could serve as a supplemental diagnostic method for distinguishing PSP from PD-3 or PD-4.


Subject(s)
Multiple System Atrophy/diagnosis , Neurodegenerative Diseases/diagnosis , Parkinson Disease/diagnosis , Parkinsonian Disorders/diagnosis , Supranuclear Palsy, Progressive/diagnosis , 3-Iodobenzylguanidine , Aged , Aged, 80 and over , Basal Ganglia/diagnostic imaging , Basal Ganglia/pathology , Cerebral Cortex/diagnostic imaging , Cerebral Cortex/pathology , Cerebrovascular Circulation , Cysteine/analogs & derivatives , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Multiple System Atrophy/diagnostic imaging , Neurodegenerative Diseases/diagnostic imaging , Organotechnetium Compounds , Parkinson Disease/diagnostic imaging , Parkinsonian Disorders/diagnostic imaging , Radiopharmaceuticals , Supranuclear Palsy, Progressive/diagnostic imaging , Tomography, Emission-Computed, Single-Photon
17.
Behav Neurol ; 24(2): 123-32, 2011.
Article in English | MEDLINE | ID: mdl-21606573

ABSTRACT

This study investigated the cognitive profile and the cerebral perfusion pattern in a highly educated 70 year old gentleman with posterior cortical atrophy (PCA). Visuo-perceptual abilities, spatial memory, spatial representation and navigation, visuo-spatial mental imagery, semantic and episodic-autobiographical memory were assessed. Regional cerebral blood flow (rCBF) was imaged with SPECT. Cognitive testing showed visual-perceptual impairment, apperceptive visual and landmark agnosia, topographical disorientation with way-finding deficits, impaired map learning and poor mental image generation. Semantic memory was normal, while episodic-autobiographical memory was impaired. Reduced rCBF was found mainly in the right hemisphere, in the precentral gyrus, posterior cingulate and middle temporal gyri, cuneus and precuneus, in the left superior temporal and lingual gyri and in the parahippocampus bilaterally. Hypoperfusion in occipito-parietal regions was associated with visuo-spatial deficits, whereas deficits in visuo-spatial mental imagery might reflect dysfunction related to hypoperfusion in the parahippocampus and precuneus, structures which are responsible for spatial and imagery processing. Dissociating performance between preserved semantic memory and poor episodic-autobiographical recall is consistent with a pattern of normal perfusion in frontal and anterior temporal regions but abnormal rCBF in the parahippocampi. The present findings indicate that PCA involves visuo-spatial imagery deficits and provide further validation to current neuro-cognitive models of spatial representation and topographical disorientation.


Subject(s)
Atrophy/physiopathology , Cerebral Cortex/physiopathology , Cognition/physiology , Dementia/physiopathology , Imagination/physiology , Neurodegenerative Diseases/physiopathology , Aged , Atrophy/diagnostic imaging , Atrophy/psychology , Brain Mapping , Cerebral Cortex/diagnostic imaging , Cerebrovascular Circulation , Dementia/diagnostic imaging , Dementia/psychology , Humans , Image Processing, Computer-Assisted , Male , Mental Recall/physiology , Neurodegenerative Diseases/diagnostic imaging , Neurodegenerative Diseases/psychology , Neuropsychological Tests , Tomography, Emission-Computed, Single-Photon
18.
Acta Vet Hung ; 56(3): 293-301, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18828481

ABSTRACT

The objective of this work was to evaluate the long-term efficacy of a proposed therapeutic protocol in 12 dogs with a tentative diagnosis of degenerative myelopathy, followed-up for a 6-month period. Twelve dogs fulfilling the antemortem inclusion criteria (breed, age, adequate vaccination, history of progressive posterior ataxia and/or paraparesis, no radiographic and myelographic abnormalities in the spinal cord and vertebral column) were allocated. All these dogs presented signs of thoracolumbar syndrome (T3-L3), scored as grade I (mild to moderate ataxia and paraparesis) in 10 and grade II (severe ataxia and ambulatory paraparesis) in 2 cases. Treatment included the use of epsilon-aminocaproic acid and N-acetylcysteine, supplemented with vitamins B, C and E. Prednisolone was given for the first two weeks and upon worsening of neurological signs. Daily exercise, performed as walking or swimming, was strongly recommended. Clinicopathological evaluation was normal in all 12 dogs, and survey radiographs and myelograms did not show spinal cord compression. Magnetic resonance imaging (MRI), performed only in 4 dogs, did not disclose compressive disorders or intramedullary lesions. Neurological signs were progressively worsening in all 12 animals, eventually resulting in severe paraparesis (grade III) or paraplegia (grade IV). The applied medications do not appear to be an attractive alternative to conservative management (physiotherapy) or euthanasia in canine degenerative myelopathy, irrespective of its chronicity.


Subject(s)
Dog Diseases/therapy , Neurodegenerative Diseases/veterinary , Physical Conditioning, Animal/physiology , Animals , Disease Progression , Dog Diseases/diagnostic imaging , Dog Diseases/pathology , Dogs , Female , Genetic Predisposition to Disease , Lameness, Animal/etiology , Lumbar Vertebrae/diagnostic imaging , Lumbar Vertebrae/pathology , Magnetic Resonance Imaging/veterinary , Male , Myelography/veterinary , Neurodegenerative Diseases/diagnostic imaging , Neurodegenerative Diseases/pathology , Neurodegenerative Diseases/therapy , Severity of Illness Index , Thoracic Vertebrae/diagnostic imaging , Thoracic Vertebrae/pathology , Treatment Failure
19.
Eur Neurol ; 44(1): 12-21, 2000.
Article in English | MEDLINE | ID: mdl-10894990

ABSTRACT

Five patients with clinical features of corticobasal degeneration (CBD) were studied with PET imaging. The main clinical findings included a unilateral extrapyramidal motor disorder, without significant response to levodopa, as well as clumsiness, dysarthria, apraxia and a clear asymmetry of neurological signs. PET studies with (18)F-labeled 2-deoxy-2-fluoro-D-glucose disclosed mainly a significant hypometabolism in the thalamus and motor cortex controlateral to the more affected limbs. Additional relationships between individual clinical signs and PET data were also found. We concluded that PET findings supported the clinical diagnosis of CBD, although the specific pattern related to this condition needs to be more precisely defined. Further studies are especially needed to correlate clinical data and PET results with pathological examination.


Subject(s)
Blood Glucose/metabolism , Cerebral Cortex/diagnostic imaging , Neurodegenerative Diseases/diagnostic imaging , Tomography, Emission-Computed , Aged , Basal Ganglia/diagnostic imaging , Basal Ganglia/pathology , Brain Mapping , Cerebral Cortex/pathology , Dominance, Cerebral/physiology , Energy Metabolism/physiology , Fluorodeoxyglucose F18 , Humans , Male , Middle Aged , Motor Cortex/diagnostic imaging , Motor Cortex/pathology , Neurodegenerative Diseases/pathology , Neurologic Examination , Thalamus/diagnostic imaging , Thalamus/pathology
SELECTION OF CITATIONS
SEARCH DETAIL